Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.19.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 17,896,821 $ 22,154,251
Short-term investments 5,611,538 5,570,027
Accounts receivable 79,047 28,538
Prepaid expenses and other current assets 818,662 961,317
Total Current Assets 24,406,068 28,714,133
Property and Equipment, net 621,419 643,146
Other Assets    
In-process R&D 5,866,000 5,866,000
Goodwill 2,189,338 2,189,338
Right-of-use asset 463,910
Deposits 351,220 351,220
Total Other Assets 8,870,468 8,406,558
Total Assets 33,897,955 37,763,837
Current Liabilities    
Accounts payable 1,618,812 974,619
Deferred revenue 340,627 1,032,539
Contingent consideration, current portion 1,209,000 1,187,000
Operating lease liability, current portion 166,142
Accrued expenses and other liabilities 948,906 1,678,051
Total Current Liabilities 4,283,487 4,872,209
Long Term Liabilities    
Contingent consideration, net of current portion 2,010,515 1,918,225
Deferred tax liability 361,911 316,733
Deferred revenue, net of current portion 200,000 200,000
Operating lease liability, net of current portion 304,997
Other long-term liabilities 261,065 213,724
Total Liabilities 7,421,975 7,520,891
Commitments and Contingencies
Stockholders' Equity    
Common stock, $.0002 par value; 100,000,000 shares authorized, 34,093,067 and 32,492,144 shares issued and outstanding at March 31, 2019 (unaudited) and December 31, 2018, respectively 6,819 6,499
Additional paid-in capital 116,943,119 114,883,135
Accumulated deficit (90,295,656) (84,580,180)
Accumulated other comprehensive loss (28,093) (19,904)
Total Stockholders' Equity- Heat Biologics, Inc. 26,626,189 30,289,550
Non-Controlling Interest (150,209) (46,604)
Total Stockholders' Equity 26,475,980 30,242,946
Total Liabilities and Stockholders' Equity $ 33,897,955 $ 37,763,837